Dareon-Lung-1 will test obrixtamig plus Tecentriq and chemo in small-cell lung cancer.
ApexOnco Front Page
Recent articles
The Sentry trial hits on spleen volume reduction, but misses on symptoms.
But this comes in second-line breast cancer, a use the group isn’t pursuing.
Ascentage hopes to become a new force in BTK.
Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Erda-iDRS maintains its promise in FGFR mutants, but adverse events could give pause.
Tacti-004 is terminated for futility, and Immutep crashes 89%.
